Eribulin Mesylate:A promising new antineoplastic agent for localy advance or metastatic breast cancer

Back ground:Eribulin Mesilate is a non-taxane microtubule inhibitor used forthe treatment of patient’s with metastatic breast cancer who have previouslyreceived at least two chemotherapeutic regimens for treatment of metastaticdisease.Methods:A systemic review of the clinical effectiveness of eribulin mesylatoefor women with heavily pretreated metastatic breast cancer 4 trials were includein this systematic review.(EMBRACE=a phase 3 open label randomized studythat used Eribulin monotherapy vs. treatment of physician’s choice),(2 phase 2studies of the halichondrin B analog eribulin mesylate in patients withmetastatic breast cancer previously treated with anthracycline and taxan ±capecitabin) ,(a phase 2 study of Eribulin in Japanese patients with heavilypretreated for metastatic breast cancer with an anthracycline and a taxane.)Finding and Result:In 4 trials that were reviewed objective response rateclinical benefit rate (complete response + partial response + stable disease 6≤months PFS and median os were improve)Conclusion:Eribulin exhibit efficacy and tolerability in metastatic breast cancerwho had a heavily pretreatment.

Keywords:

Eribulin Mesilate , Capecitabin , Objective response rate , Clinical benefit rate stable disease